Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.
ESH CML 2022
In a recent interview at #IMS26, Paul Richardson of @DanaFarber discussed findings from the HORIZON study evaluating melflufen and dexamethasone in heavily pretreated, triple-class-refractory #multiplemyeloma.🩸
To discover more, click here:
➡️
#MMsm
Melflufen and dexamethasone in triple-class-refractory multiple myeloma
Paul Richardson, MD, Dana-Farber Cancer Institute, Boston, MA, discusses findings from the HORIZON study (NCT02963493) e...
ow.ly
📖 Have you had a chance to read our newest feature article, focusing on BTK inhibitors in CLL and the move beyond covalent inhibition with the emergence of non-covalent agents and BTK degraders?
Click here to check it out:
👉 https://ow.ly/NmxG5101itW
#CLLsm #Leusm #Leukemia
Which therapies are emerging for frontline R/R #FollicularLymphoma?
At #SOHO2026, @JuanAlderuccio of @SylvesterCancer shared insight into the potential of CELMoDs, BCL6 degraders, and bispecific antibodies.
Click here to watch:
🎥
#LYMsm #Lymphoma
Emerging therapies in frontline and R/R FL: CELMoDs, BCL6 degraders, and bispecific antibodies
Juan Alderuccio, MD, Sylvester Comprehensive Cancer Center, Miami, FL, discusses emerging treatment strategies for follicu...
ow.ly
🎥 Doris Hansen of @MoffittNews recently presented Phase I results for BMS-986453, a dual-targeting #CARTCell therapy targeting both BCMA and GPRC5D, in #MultipleMyeloma:
👉 👈
#CART #ImmunoOnc #MMsm #Myeloma #IMS26
Intended for healthcare
Phase I trial results: dual-targeting BCMA and GPRC5D CAR T-cell therapy in multiple myeloma
Doris Hansen, MD, Moffitt Cancer Center, Tampa, FL, discusses initial findings from the Phase I study (NCT06153251) ...
ow.ly
At the 2026 ERIC International Meeting, Alexey Danilov (@DanilovLab) of @cityofhope discussed the potential of #CARTCell therapy and bispecific antibodies in chronic lymphocytic #leukemia.🩸
Watch now:
👉
#Leusm #CLLsm #ImmunoOnc #HemOnc
Intended for
Exploring CAR-T and bispecifics in CLL: novel approaches beyond BTK and BCL2 inhibitors
Alexey Danilov, MD, PhD, City of Hope, Duarte, CA, discusses novel approaches for patients with chronic lymphocytic ...
ow.ly
ESH CML 2022
In a recent interview at #IMS26, Paul Richardson of @DanaFarber discussed findings from the HORIZON study evaluating melflufen and dexamethasone in heavily pretreated, triple-class-refractory #multiplemyeloma.🩸
To discover more, click here:
➡️
#MMsm
Melflufen and dexamethasone in triple-class-refractory multiple myeloma
Paul Richardson, MD, Dana-Farber Cancer Institute, Boston, MA, discusses findings from the HORIZON study (NCT02963493) e...
ow.ly
📖 Have you had a chance to read our newest feature article, focusing on BTK inhibitors in CLL and the move beyond covalent inhibition with the emergence of non-covalent agents and BTK degraders?
Click here to check it out:
👉 https://ow.ly/NmxG5101itW
#CLLsm #Leusm #Leukemia
Which therapies are emerging for frontline R/R #FollicularLymphoma?
At #SOHO2026, @JuanAlderuccio of @SylvesterCancer shared insight into the potential of CELMoDs, BCL6 degraders, and bispecific antibodies.
Click here to watch:
🎥
#LYMsm #Lymphoma
Emerging therapies in frontline and R/R FL: CELMoDs, BCL6 degraders, and bispecific antibodies
Juan Alderuccio, MD, Sylvester Comprehensive Cancer Center, Miami, FL, discusses emerging treatment strategies for follicu...
ow.ly
🎥 Doris Hansen of @MoffittNews recently presented Phase I results for BMS-986453, a dual-targeting #CARTCell therapy targeting both BCMA and GPRC5D, in #MultipleMyeloma:
👉 👈
#CART #ImmunoOnc #MMsm #Myeloma #IMS26
Intended for healthcare
Phase I trial results: dual-targeting BCMA and GPRC5D CAR T-cell therapy in multiple myeloma
Doris Hansen, MD, Moffitt Cancer Center, Tampa, FL, discusses initial findings from the Phase I study (NCT06153251) ...
ow.ly
At the 2026 ERIC International Meeting, Alexey Danilov (@DanilovLab) of @cityofhope discussed the potential of #CARTCell therapy and bispecific antibodies in chronic lymphocytic #leukemia.🩸
Watch now:
👉
#Leusm #CLLsm #ImmunoOnc #HemOnc
Intended for
Exploring CAR-T and bispecifics in CLL: novel approaches beyond BTK and BCL2 inhibitors
Alexey Danilov, MD, PhD, City of Hope, Duarte, CA, discusses novel approaches for patients with chronic lymphocytic ...
ow.ly
